Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Classical hematology 1Breast 1

Conditions

Breast Neoplasms 19Neoplasm Metastasis 5Triple Negative Breast Neoplasms 3Brain Neoplasms 3Stomach Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2HER2-positive Breast Cancer 2Urinary Bladder Neoplasms 1Thrombocytosis 1Solid Tumor 1Recurrence 1Rare Tumour 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Ovarian Neoplasms 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Meningioma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

Gemcitabine 406Oxaliplatin 131Fluorouracil 125130-nm albumin-bound paclitaxel 108Capecitabine 100Albumin-Bound Paclitaxel 90Leucovorin 88Irinotecan 87Radiotherapy 76Radiosurgery 64Taxes 63Cisplatin 56Erlotinib Hydrochloride 44Drug Therapy 42folfirinox 40Magnetic Resonance Spectroscopy 39pembrolizumab 35Blood Specimen Collection 33S 1 (combination) 31Pancreaticoduodenectomy 31Docetaxel 31Nivolumab 30Bevacizumab 30Biopsy 26Surgical Procedures, Operative 25Cyclophosphamide 25irinotecan sucrosofate 24Specimen Handling 24Radiation 22Standard of Care 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Pancreatic Neoplasms × neratinib × Clear all
NCT03919292 2026-04-21

Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

Virginia Commonwealth University

Phase 1/2 Recruiting
83 enrolled
Gastrointestinal

Colonic Neoplasms, Pancreatic Neoplasms, Disease Progression

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡